-16.4%
ACHR vs GSK
+48.4%
-64.8%
-67.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.1% | -2.7% | +4.8% | +2.2% |
| 7D | +4.9% | -4.2% | +9.0% | +5.1% |
| 30D | +4.3% | -7.5% | +11.8% | +4.7% |
| 3M | +1.7% | -3.3% | +5.0% | +1.5% |
| 6M | -6.9% | -9.3% | +2.5% | -6.3% |
| YTD | -22.5% | +1.6% | -24.1% | -23.2% |
| 1Y | -31.5% | +25.5% | -57.0% | -34.1% |
| All | -16.4% | +48.4% | -64.8% | -24.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling